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abstract | Diarthrodial joints are well suited to intra‑articular injection, and the local delivery of therapeutics in 
this fashion brings several potential advantages to the treatment of a wide range of arthropathies. Possible 
benefits over systemic delivery include increased bioavailability, reduced systemic exposure, fewer adverse 
events, and lower total drug costs. Nevertheless, intra‑articular therapy is challenging because of the rapid 
egress of injected materials from the joint space; this elimination is true of both small molecules, which 
exit via synovial capillaries, and of macromolecules, which are cleared by the lymphatic system. In general, 
soluble materials have an intra‑articular dwell time measured only in hours. Corticosteroids and hyaluronate 
preparations constitute the mainstay of FDA‑approved intra‑articular therapeutics. Recombinant proteins, 
autologous blood products and analgesics have also found clinical use via intra‑articular delivery. Several 
alternative approaches, such as local delivery of cell and gene therapy, as well as the use of microparticles, 
liposomes, and modified drugs, are in various stages of preclinical development.
Evans, C. H. et al. Nat. Rev. Rheumatol. advance online publication 5 November 2013; doi:10.1038/nrrheum.2013.159
Introduction 
For a drug with a direct mode of action, local adminis-
tration offers several advantages over systemic delivery, 
including increased bioavailability, reduced systemic 
exposure, fewer off-target effects and adverse events, 
and lower total drug cost. Being discrete cavities, most 
diarthrodial joints are well suited to local drug delivery 
via intra-articular injection. Osteoarthritis (Oa), which 
affects individual joints, and polyarticular inflammatory 
pathologies, including rheumatoid arthritis (ra) and 
gout, have high incidence and long-term therapeutic 
need; moreover, current treatment options are inadequate 
for many patients. thus, tremendous interest has been 
generated in achieving successful localization of thera-
peutics at the pathological site, to maximize efficacy and 
reduce drug cost. Most common disorders of diarthro-
dial joints—with ra the exception—are not accompanied 
by clinically significant extra-articular manifestations, 
which makes the prospect of local therapy particularly 
appealing. reflecting the growing interest in this field, 
the second international symposium on intra-articular 
treatment was held in Barcelona in October 2013.1
this review discusses therapeutics that can be com-
fortably introduced into the joint in an outpatient setting 
via a small-gauge needle. arthroscopy and other surgical 
procedures are, therefore, excluded. First, we describe 
how the biology of the joint controls the entry and clear-
ance of exogenous molecules. next, we outline current 
uses of intra-articular therapy in rheumatology and 
orthopaedics. Finally, we consider the development of 
emerging strategies such as drug-delivery particles, gene 
transfer and cell-based therapies.
The pharmacokinetics of the joint 
the joint-space ‘dwell time’ of a therapeutic agent is influ-
enced by the rate at which the molecule reaches and is 
cleared from the synovial fluid. the former parameter 
depends on the size and route of administration of the 
drug, whereas the rate of efflux of a soluble agent is largely 
independent of these properties (Figure 1). systemically 
delivered, soluble substances enter the joint space via the 
capillary network of the subsynovium, which is highly 
vascularized; small molecules also leave via the vascula-
ture, whereas larger substances such as proteins exit via 
the lymphatic system.2
Drug delivery to cartilage 
For certain indications, it is necessary to deliver therapeu-
tics to cartilage. Because cartilage is avascular, it is ineffi-
ciently targeted by systemic delivery of drugs, which must 
first reach the synovial fluid and then diffuse through 
the cartilagenous extracellular matrix (eCM). unless 
damaged, this matrix is highly anionic and increasingly 
impermeable to molecules much greater than the size of 
albumin (~67 kDa), depending upon their charge and con-
formation.3 intra-articular therapy improves delivery to 
cartilage and can therefore increase thera peutic efficacy, 
but in doing so it exposes chondro cytes to higher concen-
trations of drugs. in developing intra-articular therapeu-
tics, therefore, investigators must be aware of the potential 
for exposing previously unrecog nized chondrotoxicity.
Joint-space entry is size-dependent 
to enter the joint space from the synovial circulation, 
solutes need to pass through two layers of resistance 
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in series: the capillary wall and the eCM of the synovial 
intima.4 the endothelial lining of the subsynovial capil-
laries is fenestrated, with the fenestrations orientated 
towards the joint space; this orientation facilitates the 
directed exit of solutes from these capillaries. Because 
the synovium has no basement membrane to impede mol-
ecular transit,5 small molecules pass freely through the 
vascular endothelium, and the major determinant of their 
entry into the joint space is their rate of diffusion through 
the synovial interstitium. with this entry route being 
dependent on the small pores of the capillary endothelium 
and the tight spaces of the interstitial matrix, unimpeded 
transport through passive diffusion occurs only for small 
molecular weight (Mw) compounds, typically <10 kDa.
For larger molecules, the endothelial lining imposes 
a size-dependent sieving effect on the rate of passage 
(Figure 2). For example, the concentration ratio of normal 
synovial fluid:serum for albumin is ~0.40; for the much 
larger molecules α2–macroglobulin and igG this ratio 
drops to 0.03–0.05.6 Fibrinogen, with a Mw of 340 kDa, 
is rarely found in synovial fluid in the absence of inflam-
mation, probably because of its very high stokes radius 
(that is, hydro dynamic radius).6
Inflammation increases synovial permeability 
synovial inflammation is a key feature of many joint 
pathologies; most notably observed in ra and following 
joint injury, it is also present in Oa.7 in an inflamed joint, 
capillary permeability increases, thereby enhancing the 
entry of macromolecules into the joint space. evidence of 
this effect can be found in the protein content of synovial 
fluid from patients with ra, which is increased in compari-
son with healthy controls, as well as notable increases in 
the proportion of large to small molecular components 
in ra samples.6,8
macromolecules have short dwell time 
although entry of macromolecules into joints is con-
strained, their removal from joints occurs via the lymphatic 
system in a fashion that, unlike their entry, is independent 
of size (Figure 1). the rate of removal of macro molecules 
from the joint is increased in patients with ra, reflecting 
enhanced drainage from the joint space due to greater 
synovial lymph flow.9
Key points
 ■ Getting therapeutics into joints in a targeted and sustained fashion is difficult
 ■ Intra‑articular injection solves the delivery problem and brings several 
additional advantages over systemic administration, including increased 
bioavailability, reduced systemic exposure, fewer off‑target effects and  
lower costs
 ■ Soluble drugs exit joints rapidly, via the capillaries (in the case of small 
molecules) and lymphatic system (for macromolecules)
 ■ Strategies for extending the intra‑articular half‑lives of therapeutics include the 
use of small particles, drug modification and gene transfer
 ■ Delivery of hyaluronate and corticosteroids accounts for the majority of intra‑
articular injections; additional therapeutics include recombinant proteins, 
autologous blood products and analgesics
 ■ Clinical trials involving the intra‑articular injection of mesenchymal stem cells 
have multiplied enormously in recent years
Because lymphatic drainage is highly efficient, the intra-
articular dwell time of proteins in joints is typically a few 
hours or less. this timescale presents obvious problems 
when attempting to treat chronic joint disorders with large 
molecules. although intra-articular injection can circum-
vent the entry restrictions imposed by synovial sieving 
(Figure 1), it cannot avoid rapid lymphatic clearance of 
a therapeutic agent. the need to increase intra-articular 
dwell time was a major reason why local gene delivery to 
joints was suggested as a therapeutic strategy.10 similar 
time constraints exist for small molecules, which rapidly 
diffuse from the joint via the synovial capil laries. Larsen 
et al.11 have tabulated the half-lives of various substances 
within the joints of experimental animals as well as within 
healthy and arthritic human joints. the values reported 
range from 0.23 h for acridine orange (Mw 370 Da) to 
1.23–13.1 h for albumin and 26.3 h for hyaluronic acid 
(Mw 3 × 106 Da). intra-joint half-lives of nsaiDs and 
soluble steroids cluster at around 1–4 h.11 these values 
illustrate the challenges facing in tra- articular therapy, 
especially for chronic conditions.
Intra-articular injection 
Pros and cons versus systemic delivery 
although various prodrug12 and particle-based13 strategies 
for targeting drugs to inflamed joints through the systemic 
circulation are in development, intra-articular injection 
remains the method of choice for local therapeutic delivery. 
this route of administration overcomes concerns about the 
extent of bioavailability, unknown or uncontrollable drug 
dosing, the effects of drug binding to systemic molecules, 
and other drug modifications that can limit the efficacy of 
a substance administered via systemic delivery. Moreover, 
it eliminates many patient compliance issues.
nevertheless, in many countries, intra-articular injec-
tions are performed almost exclusively by rheumatologists 
and orthopaedists; this requirement for specialist time is 
limiting when repetitive, serial injections are neces sary. the 
exclusion of the general practitioner places intra-articular 
delivery at a logistical disadvantage compared with oral and 
self-administered, subcutaneous administration. However, 
the development of technologies such as fluoroscopy and 
ultrasonography to ensure accuracy could expand the use of 
intra-articular injection to a wider spectrum of physicians.
Clinical history 
Clinical use of intra-articular injections dates back to the 
1930s when formalin, glycerin, lipodol, lactic acid and 
petroleum jelly were among the first substances injected 
into patients with arthritis.14 widespread and persistent 
use of the technique began in the 1950s when intra- 
articular injections of corticosteroids became common for 
treating patients with ra.15 More recently, the use of intra-
articular injections has expanded greatly with the approval 
of therapeutics based on hyaluronate for the treatment of 
Oa (discussed later in this manuscript).
Delivery and adverse events 
accuracy of injection is an issue, even for large, accessible 
joints such as the knee where as many as 50% of intended 
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intra-articular injections by experienced physicians can end 
up in extra-articular locations.16,17 nevertheless, simkin18 
has argued that, because the synovial fluid is contiguous 
with the interstitial fluid of the synovium, any injection 
within the joint capsule is close enough to the target site. 
accu racy is improved by fluoroscopic and ultrasound guid-
ance techniques, and these tools are particularly valuable 
for treating joints, such as the hip, that are difficult to access.
Other than injection-site reactions in certain indivi duals, 
little morbidity is associated with intra-articular injec-
tion of corticosteroids or hyaluronate, the main concern 
being infection. incidences of infection of 1 in 3,000 to 1 
in 50,000 have been reported in the literature.19 although 
these rates are low, the increased cumulative risk of infec-
tion with repeat administration and concern about possible 
adverse effects of corticosteroids on cartilage create reluc-
tance to inject joints too frequently. no rigid guidelines 
on this matter exist, but most practitioners are reluctant 
to inject a joint more than once every 3–6 months, unless 
delivering agents based on hy aluronate, which can require 
multiple injections.
Intra-articular therapeutics 
Corticosteroids 
a long history of intra-articular corticosteroid use exists 
for patients with ra.15 although the introduction of 
tnF antagonists has reduced the need for intra-articular 
cortico steroids in this disease, they are still administered 
to individual symptomatic joints that fail to respond to 
systemically delivered drugs.
Joint-space kinetics 
Corticosteroids are highly hydrophobic, small (<700 Da) 
hydrocarbons that can be transported into the joint space 
after systemic administration through trans-capillary dif-
fusion, although resulting bioavailability in the synovial 
fluid is much reduced in comparison with the systemic 
compound. thus, one motivation for developing intra-
articular delivery of corticosteroids has been to increase 
effective dosing. Besides increasing the rate of entry to 
the joint, intra-articular injection also enables delivery 
of modified molecules that would be incompatible with 
systemic delivery—such modifications can increase the 
intra-joint retention of corticosteroid formulations. Drug 
clearance is thus reduced through the use of excipients 
(for example, polyethylene glycol [PeG], dextran or 
p olysorbate-based suspension) that promote retention 
of the drug in an aqueous solution, or salts that promote 
retention of the steroid in a crystalline form over long 
periods of time. in this manner, the drugs are complexed 
with salts or polymers and suspended in aqueous solutions 
that act to sequester the drug from the synovial fluid and 
delay clearance from the joint space.20,21 nevertheless, the 
intra-articular half-lives achieved for corticosteroids have 
rarely been found to exceed 12 h, owing to the very low 
molecular weights of these compounds.21
Roles in rheumatology and orthopaedics 
intra-articular corticosteroids are a mainstay of therapy in 
Oa22 and are typically reserved for joints with refractory 
pain and/or effusion. although pain and other symptoms 
are reduced for up to 4 weeks following injection,22 there 
is concern that prolonged exposure to steroids might 
adversely affect articular cartilage and thus accelerate 
the progress of the disease. For this reason, many physi-
cians limit the use of corticosteroids to 3–4 intra-articular 
in jections annually into any given joint with Oa.
Corticosteroids are also administered for gout, and for 
treating many other circumstances in which the joint is 
painful or inflamed. their use after injury to the joint to 
prevent the development of post-traumatic Oa might 
also be possible; the results of a cartilage-explant study 
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Figure 1 | How soluble molecules get into and out of joints. Macromolecules  
in the circulation enter the joint via the synovial capillaries and are sieved by the 
fenestrated endothelium of the capillaries (see Figure 2). Small molecules also 
enter via the capillaries, but the major resistance to their entry is provided by the 
ECM of the synovial interstitium. Intra‑articular injection bypasses both of these 
constraints to entry. However, both large and small molecules rapidly exit the joint, 
via the lymphatic system and small blood vessels, respectively. Abbreviations: 
ECM, extracellular matrix; IA, intra‑articular.
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published in 2011 indicate that short-term glucocorticoid 
therapy prevents the catabolic consequences of mechanic al 
injury and proinflammatory cytokines.23
Formulation and use 
a number of different corticosteroid formulations are 
available for intra-articular injection (Box 1). Few studies 
have compared their effectiveness; those that have done 
so suggest that triamcinolone hexacetonide might be of 
greater benefit than other preparations in ra,24,25 juvenile 
idiopathic arthritis26 and in Oa,27 perhaps because it is 
least soluble. 
several studies have suggested that intra-articular gluco-
corticoid injection for knee synovitis has a better outcome 
in resting patients than in mobile patients. nevertheless, 
on the basis of objective measures of serum levels of triam-
cinolone hexacetonide, cortisol and adreno corticotropic 
hormone, immobilization does not seem to retard gluco-
corticoid resorption after intra- articular administration.28
hyaluronate 
intra-articular administration of the eCM component 
hyal uronate is very common for the treatment of pain 
in joints with Oa that has not responded to nsaiDs or 
analge sics such as acetaminophen. seven different hyal-
uronate preparations have been approved by the FDa 
for injection into the knee (Box 1); a growing literature 
also investigates their use in other joints such as the hip, 
sh oulder, facet joint and the small joints of the hands 
and feet.29
Joint-space kinetics 
unmodified hyaluronate reportedly resides within the 
joint space for 12–24 h following intra-articular deliv-
ery.30 Historically considered to be the main lubricant 
of the joint (before the discovery of lubricin, see below), 
hyaluronate is believed to act as a viscosupplement fol-
lowing intra-articular injection, replacing or supplement-
ing the endogenous molecule.31 as such, its longevity 
and persistence within the joint space are crucial to its 
function, which depends on its physical presence. thus, 
investigators are developing very high molecular weight, 
or crosslinked, hyaluronate preparations that can report-
edly contribute to intra-articular half-lives exceeding 48 h 
in animal studies;32 crosslinked preparations are also in 
clinical use (Box 1).
Clinical performance and development 
Given the prevalence of Oa and the current lack of  disease- 
modifying therapies, intra-articular injections of hya-
luronate are widely used and represent one of the most 
common reasons for intra-articular injection. However, 
opinion remains divided on their efficacy and consider-
able divergence is reported in the literature, including in 
the contrasting results of meta-analyses.33,34 Potentially, 
improved understanding of how eCM molecules such as 
hyaluronate influence the intra-articular pathophysiology 
of the joint in Oa will lead to more effective alternatives. 
indeed, interest is high in the possible intra-articular appli-
cation of another lubricating macromolecule, lubricin, 
for the treatment of Oa.35 Lubricin, also known as pro-
teoglycan 4, is thought to be particularly important for 
cartilage-on-cartilage lubrication and to be more effective 
than hyaluronate in this regard. its absence in humans 
with the disease  camptodactylyl-arthropathy-coxa vara-
pericarditis syndrome36 or knockout mice37 leads to car-
tilage degeneration. intra-articular injection of lubricin 
prevents the development of post-traumatic Oa in rats.38
Biologic agents 
Joint-space kinetics of proteins 
the success of infliximab, etanercept, adalimumab and 
other anti-tnF agents as systemic treatments for ra has 
led to their intra-articular use in individual joints that do 
not respond to systemic therapy.39 Other recombinant 
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Figure 2 | Concentration ratios of proteins between serum 
and synovial fluid. Entry of macromolecules into the synovial 
fluid from the systemic circulation is normally impeded as a 
function of molecular size (see also Figure 1).6,96,97
Box 1 | Approved* drugs for intra‑articular administration
Corticosteroids
 ■ Hydrocortisone tebutate
 ■ Betamethasone acetate
 ■ Betamethasone sodium phosphate
 ■ Methylprednisone acetate
 ■ Triamcinolone acetonide
 ■ Triamcinolone diacetate
 ■ Triamcinolone hexacetonide
 ■ Dexamethasone sodium phosphate
hyaluronates
 ■ Hyalgan (5 injections, not crosslinked)
 ■ Supartz (5 injections, not crosslinked)
 ■ Orthovisc (3 injections, not crosslinked)
 ■ Euflexxa (3 injections, not crosslinked)
 ■ Gel‑One (1 injection, crosslinked)
 ■ Synvisc (3 injections, crosslinked)
 ■ Synvisc‑one (1 injection, crosslinked)
Various analgesics
*FDA approved.
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proteins, such as the iL-1 receptor antagonist anakinra 
and the anti-iL-1β monoclonal antibody canakinumab 
have followed suit and are being trialled as joint injec-
tions (table 1). these agents are typically soluble proteins 
with kinetics of joint clearance that, in line with the discus-
sion in the “Pharmacokinetics of the joint” section, can 
be expected to generate half-lives of approximately 2–4 h.
Systemic versus intra-articular anti-TNF agents 
Clinical trials of joint injections of the tnF antagonist 
etanercept have been pursued for the treatment of both 
ra and refractory knee joint synovitis (table 1). similarly, 
intra-articular delivery of infliximab for the treatment of 
Oa and spondyloarthritis has been compared with intra-
venous delivery of the biologic agent or corticosteroid. 
although no randomized controlled trial has been pub-
lished, anecdotal reports indicate outcomes of success 
in treating spondyloarthritis, ra and Oa.40–42 However, 
intra-articular delivery of proteinaceous anti-tnF agents 
has not become a mainstay of clinical care.
Clinical progress with other proteins 
recombinant interleukin-1 receptor antagonist (riL-1ra; 
anakinra) has been evaluated as an intra-articular treat-
ment for Oa. Despite the encouraging results of an open-
label pilot study,43 a subsequent phase ii study showed 
only short-term benefit.44 this finding might reflect the 
rapid egress of riL-1ra, a 17 kDa protein, from the joint. 
nevertheless, a single, intra-articular injection of ana-
kinra immediately after injury prevented post- traumatic 
Oa in a mouse fracture model of the disease.45 Of interest, 
the same dose administered daily for 1 month by a sub-
cutaneous osmotic pump had no effect. in a phase i clini-
cal study, intra-articular injection of anakinra improved 
short-term outcomes after rupture of the anterior cruciate 
ligament.46 as for tnF antagonists and any new indica-
tion, the time, amount and dosing to achieve a therapeutic 
concentration in the joint space, albeit for a short duration, 
are critical but unknown variables.
intra-articular delivery of bone morphogenetic pro-
tein 7 (BMP7) showed promising results in a phase i clini-
cal study in patients with Oa of the knee,47,48 but data from 
the subsequent phase ii trial have not yet been published.49 
Fibroblast growth factor 18 (FGF18) and canakinumab 
are also in current clinical trials testing their efficacy as 
intra-articular treatments for Oa (table 1).
autologous blood products 
Platelet-rich plasma (PrP) is widely used by the ortho-
paedic community as a treatment for a variety of musculo-
skeletal problems, including Oa, despite scant solid 
evidence to commend this approach.50 a few case reports 
and small clinical series in which PrP has been injected 
into joints with Oa have been published; however, the 
results are equivocal and much more research is needed.51 
Clinical experiences are difficult to compare, because dif-
ferent preparations of PrP have different compositions 
and variable effects on inflammation.52 a concentrated 
PrP product known as autologous Protein solution is 
being evaluated in patients with Oa.53,54
autologous conditioned serum is obtained from incu-
bated blood and injected into joints with Oa or other 
painful conditions. whole blood is incubated with 
m edical-grade, etched glass beads that induce the synthe-
sis of anti-inflammatory molecules, including iL-1ra.54,55 
after filtration, the conditioned serum is injected into the 
joint. apart from rare cases of acute inflammation after 
intra-articular administration of this complex preparation, 
the overall incidence of complications seems to be low.56 
a randomized controlled clinical trial in 376 patients with 
knee Oa demonstrated a therapeutic effect superior to that 
achieved with the injection of saline or hyaluronic acid.57 
analgesics 
Local anaesthetics have FDa approval as injections for the 
production of local or regional anaesthesia or analge sia. 
intra-articular analgesia is often used after joint surgery 
and occasionally in joints with Oa. Lidocaine, bupi-
vacaine, ropivacaine and opiates have been evaluated as 
intra-articular analgesics, mostly for postoperative pain.14 
Botulinum toxin a has been evaluated as a therapy for 
chronic joint pain and Oa.58 Chondrolysis associated 
with the use of intra-articular local anaesthetic ‘pain 
pumps’ has been described by several groups,59–61 which 
has raised concern about the clinical use of intra-articular 
anaes thetics. Dose-dependent toxic effects of analgesics, 
including apoptosis, have been demonstrated in vitro.62 
the type and concentration of anaesthetic, as well as addi-
tives and pH, have been implicated in the chondrotoxicity 
of intra-articular analgesics.62,63 ropivocaine is less toxic 
in cultured chondrocytes and cartilage explant systems 
than bupivacaine.63
Intra-articular drug delivery systems 
as we have mentioned, low Mw compounds are cleared 
rapidly from the joint space. Furthermore, poor drug 
solubility and poor tissue distribution within the joint 
have helped to create interest in designing drug delivery 
systems specifically for the intra-articular environment. as 
we discuss here, liposomes and microparticles have con-
sequently been evaluated in the context of intra-articular 
drug delivery.
Liposomes 
Liposomes entrap primarily hydrophobic drugs in a 
lipid bilayer or lipid phase, and enable sustained release 
through liposome dissolution and slow solubilization of 
the drug. Liposome drug-loading efficiencies as high as 
90% are possible for many hydrophobic drugs and these 
vesicles are thus attractive for delivering corticosteroids 
such as triamcinolone, celocoxib, dexamethasone, and 
cortisol-21-palmitate.64–66 the longevity of the drug and its 
onset of action are dependent upon particle size, with 
results suggesting that liposomes can extend drug activity 
by as much as 14 days.64 this pharmacodynamic extension 
might be attributable to efficient endocytosis of the lipo-
some and/or to prolonged drug re- solubilization. Particle 
sizes of 100 nm–5 μm seem to be suitable for achieving 
prolonged drug retention, with too rapid clearance of drug 
from liposomes noted for much smaller particles.11,67 
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Table 1 | Trials of recombinant proteins and synthesized peptides delivered by intra‑articular injection 
Study name; Clinicaltrials.gov identifier Drug* and 
comparator 
Indication Study phase; 
design 
Current status; results 
reported‡ 
Intra‑Articular Injection of Etanercept in Patient Suffering 
From Rheumatoid Arthritis: a Double‑Blind Randomized 
Study; NCT0052218498
Etanercept vs steroid RA Phase III; 
Double‑blind RCT
Completed Nov 2006; no 
results reported
Evaluation of The Efficacy And Safety of Intra‑Articular 
Etanercept in Patients with Refractory Knee Joint Synovitis; 
NCT0067878299
Etanercept vs placebo Refractory knee‑joint 
synovitis: RA, PsA  
and SpA
Phase II; 
single‑blind RCT
Completed Dec 2007;  
no results posted 
(associated biomarker 
study published100) 
Intraarticular Injection of Infliximab; NCT00521963101 Infliximab vs 
corticosteroid
Monoarthritis of the 
knee, or residual knee 
inflammation in 
controlled polyarthritis
Phase II/III; 
double‑blind RCT
Recruitment status 
unknown, last update 
Aug 2007
Seronegative Oligoarthritis of the Knee Study (SOKS); 
NCT01216631102
IA vs IV infliximab vs 
methylprednisolone
SpA Phase II; 
double‑blind RCT
Recruitment status 
unknown, no updates 
since record created  
in 2010
Treatment Of Knee Osteoarthritis with Intra‑Articular 
Infliximab; NCT01144143103
Infliximab vs 
methylprednisolone  
vs placebo
Knee OA Phase IV; 
double‑blind RCT
Completed Dec 2010;  
no results posted
Study of Intra‑articular DLX105 Applied to Patients with 
Severely Painful Osteoarthritis of the Knee; NCT00819572104
DLX105§ vs placebo Severely painful  
knee OA
Phase I/IIa; 
double‑blind RCT
Completed Sep 2010;  
no results posted
Study to Prevent Cartilage Damage Following Acute Knee 
Injury; NCT00332254105
Anakinra vs placebo Severe knee injury Phase I/II; 
double‑blind RCT
Completed Jun 2007; 
temporary improvement  
in KOOS score46
Treatment for Patients with Osteoarthritis (OA) of the Knee; 
NCT00110916106
Anakinra vs placebo Painful knee OA Phase II; 
double‑blind RCT
Completed Feb 2005; 
results published (anakinra 
not better than placebo)44
To Determine the Safety, Tolerability, Pharmacokinetics and 
Effect on Pain of a Single Intra‑articular Administration of 
Canakinumab in Patients with Osteoarthritis in the Knee; 
NCT01160822107
Canakinumab vs 
placebo injection, with 
or without oral naproxen 
vs oral placebo 
Mild‑to‑moderate  
knee OA
Phase II; 
double‑blind RCT
Completed; raw results 
posted Sep 2012, no 
analysis available 
A Phase 1, Double‑Blind, Randomized, Single Dose 
Escalation Safety Study of Intra‑articular OP‑1 in Subjects 
with Osteoarthritis of the Knee (Knee OA); NCT0045615747
BMP7 vs placebo Knee OA Phase I; 
double‑blind RCT
Completed; results 
published (support 
continued development)48 
Double‑Blind, Randomized, Single Dose Escalation  
Safety Study of Intraarticular Bone Morphogenic Protein  
(38A BMP‑7) in Subjects with Osteoarthritis (OA) of the 
Knee; NCT01133613108
BMP7 vs placebo Knee OA Phase I; 
double‑blind RCT
Completed Oct 2011;  
no results posted
Dose Finding Study of Bone Morphogenetic Protein 7 
(BMP‑7) in Subjects with Osteoarthritis (OA) of the Knee; 
NCT0111104549
BMP7 vs placebo Knee OA Phase II; 
double‑blind RCT
Completed Aug 2011;  
no results posted
AS902330 in Cartilage Injury Repair (CIR); NCT01066871109 FGF18 vs placebo Acute injury of knee 
cartilage
Phase II; 
double‑blind RCT
Ongoing, recruitment 
ended, no estimated 
completion date
Study of AS902330 (rhFGF‑18) Administered Intra‑articularly 
in Patients with Knee Primary Osteoarthritis who Are 
Candidates for Total Knee Replacement; NCT00911469110
FGF18 vs placebo Knee OA eligible  
for TJR
Phase I; 
double‑blind RCT
Completed Jun 2010;  
no results posted
A Multicenter Study of rhFGF 18 in Patients with Knee 
Osteoarthritis Not Requiring Surgery; NCT01033994111
FGF18 vs placebo Knee OA not requiring 
surgery
Phase I; 
double‑blind RCT
Data collection completed; 
no results posted
A Study to Investigate the Safety and Effectiveness of 
Different Doses of Sprifermin (AS902330) in Patients with 
Osteoarthritis of the Knee (FORwARD); NCT01919164112
FGF18 vs placebo Knee OA Phase II; 
double‑blind RCT
Recruiting patients
A Multicenter trial of AS902330 (Recombinant Human 
Fibroblast Growth Factor‑18) or Placebo After Microfracture 
Surgery for Cartilage Injury of the Knee; NCT01689337113
FGF18 vs placebo Microfracture of the 
femoral articular 
surfaces with intact 
subchondral bone
Phase II; 
double‑blind RCT
Recruiting patients
Efficacy and Safety Study of Intra‑articular Multiple Doses of 
Icatibant in Patients with Painful Knee Osteoarthritis; 
NCT00303056114
Icatibant|| vs placebo Knee OA Phase II; 
double‑blind RCT
Completed Jul 2007;  
no results posted
*IA delivery unless stated otherwise. ‡As of September 2013. §DLX105 is a single‑chain antibody fragment anti‑TNF agent. ||Icatibant is a chemically‑synthesized 10‑amino acid peptide 
antagonist of bradykinin B2 receptors. Abbreviations: ACL, anterior cruciate ligament; BMP7, bone morphogenic protein 7 (also known as osteogenic protein 1); FGF18, fibroblast growth 
factor 18; IA, intra‑articular; IV, intravenous; KOOS, knee injury and osteoarthritis outcome score; OA, osteoarthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RCT, randomized controlled 
trial; SpA, spondyloarthritis; TJR, total joint replacement.
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Liposomes are less useful with more polar drugs, such 
as methotrexate, because of low drug loading ratios and a 
rapid burst release encountered in the aqueous environ-
ment of the synovial fluid.11,67 Moreover, liposomal 
prepara tions require mixing of the drug with organic 
solvents that are damaging to proteinaceous drugs. 
nevertheless, several therapeutic liposomal formulations 
are in clinical use for a variety of indications, including the 
delivery of doxorubicin in cancer (for example, DoxiltM, 
Janssen Biotech, Beerse), amphotericin for fungal infec-
tion (for example, amBisometM, astellas Pharma, tokyo) 
and cytarabine for cancer (Depocyt®, sigma-tau Pharma, 
Gaithersburg), with good safety profiles that suggest 
their potential utility for localized intra-articular deliv-
ery. Knowledge of these liposomal formulations applies, 
however, to intravenous, topical or intramuscular use, 
with only one liposomal product available for intra- 
articular delivery, a palmitylated dexamethasone, and only 
in Germany (Lipotalon®, Merckle, ulm).
Microparticles and nanoparticles 
For proteinaceous drugs and polar molecules, synthetic 
polymeric microparticles and nanoparticles might be 
more suitable than liposomes as drug delivery systems for 
the joint space. Biodegradable microparticles composed 
of polyesters (for example, PLGa, PLLa), poly anhydrides, 
and polycaprolactones have been developed for broader 
clinical applications, including the encapsulation of syn-
thetic hormones (Lupron®, abbott, illinois), tretinoin 
(retina Micro®, Orthoneutrogena, Los angeles) and ris-
peridone (riseperdal®, Janssen Pharma, Beerse) and have 
shown potential for prolonging intra-articular drug resi-
dence time in preclinical studies. For betamethasone,68,69 
methotrexate,70 diclofenac,71 sirna72 and paclitaxel,73 
for example, encapsulation in microspheres composed 
of PLLa, PLGa, or polycaprolactones contributed to 
a sustained release effect in animal models of arthritis 
that could be observed up to 21 days after delivery in 
some cases.68–71
Drug availability within the joint space after deliv-
ery within a microsphere depends on the competing 
and synergistic processes of drug diffusion from the 
polymer, erosion of the polymeric microparticle, and size- 
dependent endocytosis of the particle. as with liposomes, 
microparticles of a range of sizes can seemingly be endo-
cytosed without provoking deleterious inflammation 
(generally particles <30 µm), and a lower size limit exists 
below which little benefit of particulation is noted (50 nm). 
Drugs have also been studied following encapsulation in 
naturally derived polymeric ma terials, including chitosan 
microspheres, albumin, gelatin, e lastin-based systems and 
collagen. Overall, particle-based delivery systems have the 
potential to increase drug residence times greatly, with 
10–30-fold increases reported in pre-clinical models. a 
clinical study reported in 2013 of a PLGa-encapsulated 
corticosteroid, triamcinolone acetonide (FX006, Flexion 
therapeutics, Burlington), demonstrated residence in 
the joint space at thera peutic concentrations at 6 weeks 
after injection,74 providing some evidence of even 
longer periods of sustained release for microcapsules. 
nevertheless, no particle-based or liposome drug- delivery 
system has yet advanced past clinical trials for intra- 
articular drug delivery in the usa, possibly because of the 
need to establish cost-effective ma nufacturing processes 
and dosing strategies.
modifying drugs to increase dwell time 
Direct modification of known drugs is a widely used 
strategy to prolong their residence time in the joint. 
Conjugation of a PeG moiety to a drug—PeGylation—is 
a frequently used method to increase the bio availability 
of hydrophobic drugs and increase their molecular 
weight towards the goal of delaying systemic elimina-
tion. similarly, a thermally responsive small poly peptide, 
 elastin-like polypeptide (eLP), has been conjugated to 
protein drugs in a process called eLPylation.75 eLPylation 
leads to the temperature-controlled formation of a drug 
depot at the site of injection that has the potential to 
decrease drug clearance from the injection site. eLP has 
been conjugated to multiple drugs (including tnF and 
iL-1 antagonists)76,77 for application to intra-articular or 
perineural delivery. this approach has the potential to 
provide a 20-fold increase in intra-articular drug resi-
dence time,78 but is complicated by involving the creation 
of a novel conjugate, rather than an entrapped drug, with 
pharmacokinetics and pharmacodynamics that are not 
thoroughly studied.
Nonsurgical synovectomy with radionuclides 
when particles of phagocytosable size are injected into 
joints they are taken up by macrophages present in the 
synovium. this process has been used to achieve non-
surgical synovectomy via the incorporation of radio active 
materials in small particles, suspensions of which are 
injected into the joint. the technique is used for chronic 
synovial conditions, such as diffuse pigmented villo-
nodular synovitis and the haemorthrosis of patients with 
haemophilia, that are difficult to treat by other means. 
Historically a common treatment for ra, radioactive syn-
ovectomy has also been evaluated in Oa.79 improvements 
in pain and inflammation were noted, with the greatest 
effects seen in knees with the least radiological evidence 
of damage.79 isotopes of the lanthanide series of elements, 
such as Y90, sm153, er169 and Yb175, are particularly suited to 
this purpose.80 although radiation synovectomy is rarely 
used for Oa or ra, it is a method of choice for haemo-
philic synovitis.81 radiation synovectomy is complicated 
by rare cutaneous radiation necrosis82 and concerns about 
genotoxic effects.83
gene therapy 
Local gene transfer to the joint provides one solution to 
the problem of maintaining a sustained, therapeutic con-
centration of a gene product within a diseased joint, and 
can be accomplished by administration of cells geneti-
cally modified ex vivo84 or by the direct, intra-articular 
injection of viral or nonviral vectors.85 intra-articular 
gene therapy—as reviewed in this journal in 201186—has 
been evaluated in phase i clinical trials in patients with ra 
and Oa. a phase ii study in ra, using adeno-associated 
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Table 2 | Clinical trials involving the intra‑articular injection of cells
Study name; Clinicaltrials.gov identifier Cell type and source Indication Study phase; design Current status;* results 
reported
Clinical Trial to Assess the Safety, Feasibility, 
and Efficacy of Transferring a Potentially 
Anti‑arthritic Cytokine Gene to Human Joints 
with Rheumatoid Arthritis; NIH OBA number: 
9406 074‡ 
Autologous synovial cells 
(transduced to express 
IL‑1Ra)
RA Phase I; open label Completed; results 
published84
Safety Study of TissueGene‑C in Degenerative 
Joint Disease of the Knee (TGC‑03‑01); 
NCT00599248115
Chondrocyte, allogeneic 
(transduced to express 
TGF‑β1)
Knee OA scheduled 
for TKA
Phase I; single‑blind 
RCT
Completed May 2010; 
results published116
Study of TG‑C in Patients with Grade 3 
Degenerative Joint Disease of the Knee; 
NCT01221441117
Chondrocyte, allogeneic 
(transduced to express 
TGF‑β1)
Knee OA, KLG III Phase II; double‑blind 
RCT
Ongoing, recruitment ended, 
estimated completion date 
Oct 2014
Efficacy and Safety Study of TissueGene‑C to 
Degenerative Arthritis; NCT01671072118
Chondrocyte, allogeneic 
(transduced to express 
TGF‑β1)
Knee OA, KLG II–III Phase II; single‑blind 
RCT
Completed Jan 2013;
abstract published119 
Autologous Chondrocyte Intra‑articular 
Implantation in Patients with Severe Hip 
Osteoarthritis; NCT01500811120
Chondrocyte, autologous Severe hip OA Phase I; open label Unknown; estimated 
completion date Aug 2013
Articular Cartilage Resurfacing with 
Mesenchymal Stem Cells In Osteoarthritis  
Of Knee Joint; NCT01207661121
MSC, autologous (source 
unspecified)
Knee OA Phase I; open label Completed Nov 2010; 
no results posted
Adult Stem Cell Therapy for Repairing Articular 
Cartilage in Gonarthrosis; NCT01227694122
MSC, autologous, 
bone‑marrow‑derived
Knee OA Phase I/II; open label Study completed; no study 
results posted
Side Effects of Autologous Mesenchymal Stem 
Cell Transplantation in Ankle Joint 
Osteoarthritis; NCT01436058123
MSC, autologous, 
bone‑marrow‑derived
Ankle joint OA Phase I; open label Completed Sep 2011; 
no results posted
Stem Cell Transplantation for the Treatment  
of Knee Osteoarthritis; NCT00550524124
MSC, autologous, 
bone‑marrow‑derived
Knee OA Phase I; open label Recruiting by invitation
Intra‑Articular Autologous Bone Marrow 
Mesenchymal Stem Cells Transplantation  
to Treat Mild to Moderate Osteoarthritis; 
NCT01459640125
MSC, autologous, 
bone‑marrow‑derived
Mild‑to‑moderate 
knee OA
Phase II; open label, 
active comparator: 
hyaluronic acid
Recruiting, estimated 
completion date Mar 2014
Safety and Efficacy of Autologous Bone 
Marrow Stem Cells for Treating Osteoarthritis; 
NCT01152125126
MSC, autologous, 
bone‑marrow‑derived
OA, KLG III–IV Phase I/II; open label Recruiting by invitation, 
estimated completion date 
Jan 2012
Treatment of Knee Osteoarthritis with 
Autologous Mesenchymal Stem Cells 
(KDD&MSV); NCT01183728127
MSC, autologous, 
bone‑marrow‑derived
Knee OA, KLG II–IV Phase I/II; open label Ongoing, recruitment over, 
estimated completion date 
Jun 2013
Mesenchymal Stem Cell Transplantation in 
Osteoarthritis of Hip Joint; NCT01499056128
MSC, autologous, 
bone‑marrow derived
Hip OA Phase I; open label Completed Mar 2011;  
no results posted
The Effects of Intra‑articular Injection of 
Mesenchymal Stem Cells in Knee Joint 
Osteoarthritis; NCT01504464129
MSC, autologous, 
bone‑marrow‑derived
Knee OA Phase II; double‑blind 
RCT
Completed Nov 2012;  
no results posted
Allogeneic Mesenchymal Stem Cells in 
Osteoarthritis; NCT01453738130
MSC, allogeneic, source 
unspecified
Knee OA Phase II; double‑blind 
RCT
Ongoing, recruitment over, 
estimated completion date 
Jul 2014
Allogeneic Mesenchymal Stem Cells for 
Osteoarthritis; NCT01448434131
MSC, allogeneic, source 
unspecified
Knee OA Phase II; double‑blind 
RCT
Ongoing, recruitment over, 
estimated completion date 
Feb 2013
Treatment of Knee Osteoarthritis with Allogenic 
Mesenchymal Stem Cells (MSV_allo); 
NCT01586312132
MSC, allogeneic, 
bone‑marrow‑derived
Knee OA Phase II; double‑blind 
RCT, active comparator: 
hyaluronic acid
Active, recruiting; estimated 
completion date Dec 2013
A Phase I/II Study of Chondrogen Delivered  
by Intra‑Articular Injection Following 
Meniscectomy; NCT00225095133
MSC, allogeneic, source 
unspecified
Meniscectomy Phase I/II; double‑
blind; randomized
Completed; no results 
posted
Follow‑up Study of Chondrogen® Delivered  
by Intra‑Articular Injection Following 
Meniscectomy; NCT00702741134
MSC, allogeneic, source 
unspecified
Partial medial 
menisectomy
Phase II; double‑blind 
RCT
Recruitment status unknown, 
last update Aug 2010
Safety and Efficacy Study of MSB‑CAR001 in 
Subjects 6 weeks Post an Anterior Cruciate 
Ligament Reconstruction; NCT01088191135
MSC, allogeneic, source 
unspecified
ACL reconstruction Phase I/II; double‑blind 
RCT, active control: 
hyaluronan
Ongoing, recruitment over, 
estimated completion date 
Jun 2014
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virus to deliver etanercept, was marred by the death of one 
of the study participants, but was allowed to proceed to 
completion.87 Phase ii trials in Oa, using allogeneic cells 
expressing transforming growth factor β1, are continuing 
in Korea and the usa.86
Cell-based therapies 
the first clinical use of intra-articular cell delivery was 
in the context of gene therapy, using genetically modi-
fied, autologous synovial fibroblasts (table 2).84 since 
then, chondrocytes and blood cells have been injected 
into human joints (table 2), but by far the greatest activ-
ity surrounds the use of mesenchymal stem cells (MsCs). 
their use has increased spectacularly in the past 3 years: 
31 trials are listed in table 2; 23 of them involve MsCs 
and, of these, 20 were registered on Clinicaltrials.gov from 
2010 onwards.
as described by Barry and Murphy in this journal,88 
the potential intra-articular use of MsCs in treating Oa 
has attracted considerable attention because MsCs are 
thought to be anti-inflammatory and immunosuppressive 
mediators of tissue regeneration.89–91 encouraging pre-
clinical data have emerged92–94 in relation to preventing 
post-traumatic Oa, regenerating damaged cartilaginous 
surfaces and reducing pain. the intra-articular injection of 
MsCs derived from bone marrow or fat is widely used in 
equine medicine for the treatment of Oa and such thera-
pies are commercially available for use in animals. Only a 
few small human clinical case series have been published, 
such as a study using autologous MsCs in four people with 
knee Oa,95 with equivocal results. the immunosuppres-
sive nature of MsCs introduces the possibility that they 
can be successfully allografted, which raises the prospect 
of developing a therapy from a universal donor; such a 
step would reduce the cost and complexity of generating 
approved treatments.
Conclusions 
the intra-articular injection of therapeutic agents is an 
attractive strategy for the local treatment of joint dis-
eases. Most joints are accessible to accurate injection, 
especially when using image guidance. Given that such 
Table 2 (Cont.) | Clinical trials involving the intra‑articular injection of cells
Study name; Clinicaltrials.gov identifier Cell type and source Indication Study phase; design Current status;* results 
reported
Autologous Adipose Tissue Derived 
Mesenchymal Stem Cells Transplantation  
in Patients with Degenerative Arthritis; 
NCT01300598136
MSC, autologous, 
adipose‑tissue derived
Knee OA Phase I/II; open label Completed Mar 2012;  
no results posted
ADIPOA ‑ Clinical Study; NCT01585857137 MSC, autologous, 
adipose‑tissue‑derived
Knee OA, moderate 
or severe
Phase I; open label Active, recruiting; estimated 
completion date Apr 2015
Autologous Adipose‑Derived Stromal Cells 
Delivered Intra‑articularly in Patients with 
Osteoarthritis; NCT01739504138
MSC, autologous, 
adipose‑tissue‑derived
OA Phase I/II; open label Active, recruiting; estimated 
completion date Dec 2015
Outcomes Data of Bone Marrow Stem Cells  
to Treat Hip and Knee Osteoarthritis; 
NCT01601951139
Bone‑marrow concentrate, 
autologous
Hip and knee OA Phase unspecified; 
prospective, 
observational
Ongoing, not recruiting, no 
estimated completion date
Autologous Stem Cells in Osteoarthritis; 
NCT01485198140
Haematopoietic stem 
cells, autologous
Knee OA, KLG II–III Phase I; open label Active, recruiting; estimated 
completion date Aug 2013
Peripheral Blood‑drived Stem Cell Trial  
on Damaged Knee Cartilage (PBSC); 
NCT01076673141
Peripheral blood stem 
cells (identity unspecified)
Damaged articular 
cartilage
Phase unspecified; 
open label
Recruitment status unknown, 
last update Jul 2011
Allogeneic Mesenchymal Stem Cells  
in Osteoarthritis; NCT01453738142
MSC, source unspecified, 
allogeneic
Knee OA,
KLG II–III
Phase II; double blind Ongoing, not recruiting, 
estimated completion date 
July 2014
Autologous Adipose Tissue Derived 
Mesenchymal Progenitor Cells Therapy  
for Patients with Knee Osteoarthritis; 
NCT01809769143
Mesenchymal progenitor 
cells, autologous, 
adipose‑tissue‑derived
Knee OA Phase I/II; double blind Ongoing, not recruiting, 
estimated completion date 
October 2013
Autologous Bone Marrow Mesenchymal Stem 
Cells Transplantation for Articular Cartilage 
Defects Repair; NCT01895413144
MSC, bone marrow, 
autologous
Knee OA Phase I/II; open label Recruiting
Transplantation of Bone Marrow Derived 
mesenchymal Stem Cells in Affected Knee 
Osteoarthritis by Rheumatoid Arthritis (sic);
NCT01873625145
MSC, bone marrow, not 
stated whether autologous 
or allogeneic.
Knee OA Phase II/III; 
randomized, open‑label
Completed;
no results posted
Safety and Efficacy Study of MSB‑CAR001 in 
Subjects 6 weeks Post an Anterior Cruciate 
Ligament Reconstruction; NCT01088191146
MSC, source unspecified Knee,
ACL injury 
Phase I/II; double blind 
RCT
Ongoing, not recruiting. 
Estimated completion date, 
June 2014
*As of September 2013. ‡This trial predates ClinicalTrials.gov and thus lacks an NCT number. Abbreviations: ACL, anterior cruciate ligament; KLG, Kellgren–Lawrence grade; MSC, 
mesenchymal stem cell; OA, osteoarthritis; RCT, randomized controlled trial; TGF‑β1, transforming growth factor β1; TKA, total knee arthroplasty.
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injections cannot be administered too frequently, it is 
preferable to use reagents that have a lasting therapeu-
tic effect. However, soluble agents are rapidly cleared 
from joints, regardless of the size of the drug, and this 
transience remains a major barrier to successful therapy. 
intra-articular injection became popular in the latter half 
of the twentieth century owing to the introduction of 
intra-articular corticosteroids. today, this treatment and 
the injection of hyaluronate into joints with Oa form the 
major uses of this technique. interest in delivering recom-
binant proteins, autologous blood products, particles, 
cells and gene therapy vectors to diseased joints con tinues 
to mount. Local delivery in this fashion is potentially 
safer, less expensive and more effective than parenteral 
delivery. reducing the need for burdensome repeated 
injections of soluble therapeutics will, however, require 
better drug formulations with more lasting efficacy.
Review criteria
PubMed served as the primary database to identify relevant 
articles, initially using the search terms “intra‑articular 
AND therapy” without limiting date of publication. The list 
of articles was screened by title for articles in English, 
with a bias towards articles that were recent, clinical and 
novel. Nonclinical articles were included if they provided 
mechanistic insight or supplied preclinical advances. The 
abstracts of the selected articles were then read to identify 
relevant papers that were down‑loaded and studied in 
detail. More focused searches were then conducted using 
search terms “intra‑articular AND steroid”, “intra‑articular 
AND hyaluronan”, “intra‑articular AND protein”, “intra‑
articular AND cell” and “intra‑articular AND osteoarthritis 
AND therapy”. The authors drew on their own expertise in 
research in the area of intra‑articular therapy to identify 
additional references. www.ClinicalTrials.gov was searched 
to provide the information given in Tables 1 and 2.
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